Ruxience and Bendamustine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ruxience (rituximab-pvvr) and Bendamustine (bendamustine). Common drug interactions include clostridium difficile colitis among females and disease progression among males.

The phase IV clinical study analyzes what interactions people have when they take Ruxience and Bendamustine. It is created by eHealthMe based on reports of 23 people who take the same drugs from the FDA, and is updated regularly.

What is Ruxience?

Ruxience has active ingredients of rituximab-pvvr. eHealthMe is studying from 4,260 Ruxience users. Check the latest studies of Ruxience.

What is Bendamustine?

Bendamustine has active ingredients of bendamustine. eHealthMe is studying from 9,508 Bendamustine users. Check the latest studies of Bendamustine.

On Jul, 15, 2026

23 people who take Ruxience and Bendamustine together, and have interactions are studied.

Ruxience and Bendamustine drug interactions.

What are the common drug interactions of Ruxience and Bendamustine, by gender? *:

female:

Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
Disease progression
Chronic lymphocytic leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell))
Drug ineffective
Death
Pneumonia
Neoplasm progression (growth of tumour)
Deafness
Oedema (fluid collection in tissue)
Pyrexia (fever)

male:

Disease progression
Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Platelet count decreased
Renal failure (kidney dysfunction)
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Mantle cell lymphoma (cancer of lymphocytes, a type of white blood cell)
Neoplasm progression (growth of tumour)
Anaemia (lack of blood)
Cardiomyopathy (weakening of the heart muscle)
Deafness

What are the common drug interactions of Ruxience and Bendamustine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
Disease progression
Chronic lymphocytic leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell))
Drug ineffective
Pneumonia
Neoplasm progression (growth of tumour)

60+:

Disease progression
Cytokine release syndrome (immediate complication occurring with the use of anti-t cell antibody infusions)
Platelet count decreased
Renal failure (kidney dysfunction)
Seizure (abnormal excessive or synchronous neuronal activity in the brain)
Mantle cell lymphoma (cancer of lymphocytes, a type of white blood cell)
Death
Neoplasm progression (growth of tumour)
Anaemia (lack of blood)
Cardiomyopathy (weakening of the heart muscle)

What are the existing conditions these people have? *

Mantle Cell Lymphoma (cancer of lymphocytes, a type of white blood cell): 9 people, 39.13%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 7 people, 30.43%
Richter's Syndrome (hairy cell cancer changes in fast growing b cell cancer tumour): 5 people, 21.74%

* Approximation only. Some reports may have incomplete information.

Do you take Ruxience and Bendamustine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously